poisar

Stocks · News reference

Needham Maintains Buy on ICU Medical, Raises Price Target to $187

Benzinga Newsdesk

Needham analyst Mike Matson maintains ICU Medical (NASDAQ:ICUI) with a Buy and raises the price target from $165 to $187.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ICUI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    China Airway Management Market Forecast to 2033 - Airway Management Tubes and Intubation Accessories | Revenue, Volume, Pricing, Company Share, and Growth Opportunities

    ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.

    MDTTFXICUIAMBBY
  2. Jack Delaney

    ICU Medical CFO Brian Bonnell Sells 9,307 Shares

    ICU Medical CFO Brian Bonnell sold 9,307 shares on August 31, 2026, through a pre-planned Rule 10b5-1 trading plan established in June 2026. The sale, valued at $1.6 million, is not considered a red flag as it was scheduled in advance and Bonnell retains 62,443 shares worth $10.8 million. Analysts remain bullish on the stock with an 88% buy rating and a median price target of $195.

    ICUI
  3. Researchandmarkets.Com

    Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

    The global drug reconstitution systems market is expected to grow at a 7.0% CAGR from $5.9 billion in 2026 to $10.8 billion by 2035, driven by expanding biologic and biosimilar pipelines, increasing demand for safer drug delivery systems, and the shift toward home healthcare and self-administered therapies. Cartridges lead the market at 50% revenue share, while prefilled syringes are expected to grow faster. Asia-Pacific is projected to achieve the fastest regional growth.

    BAXICUISHTPY